USO 25243

An Interventional Phase 3, Open-Label, Randomized Study To Evaluate Efficacy and Safety of PF-08634404 In Combination With Chemotherapy Versus Pembrolizumab In Combination With Chemotherapy In Adult Participants With Advanced Or Recurrent Mismatch Repair Proficient Endometrial Cancer

Disease Types: GYN Cancer Research

Eligibility Requirements:

• Histo/cytologically confirmed endometrial cancer, including carcinosarcomas
• Pure sarcomas are excluded
• Pt must have rec/adv disease that meet one of the following criteria:
• Newly diagnosed Stage III w/ measurable disease per RECIST v1.1
• Newly diagnosed Stage IV (w/ or w/o measurable disease)
• Recurrent disease (w/ or w/o measurable disease) unlikely to be cured
by SOC
• pMMR by prospective central testing
• p53 status must be confirmed by prospective central testing
• Prior systemic tx for 1L adv/rec EC is excluded
• Plt-based adj chemo is allowed if completed >6 months prior to PD
• Hormonal tx for EC is allowed, must be discontinued at least 3 wk prior
to first dose of PF-4404
• Prior systemic immunotherapy, anti-angiogenic tx (including bevacizumab)
and small-molecule TKIs tx are excluded

For more detail on this trial CLICK HERE .

Available at:

• Chesapeake
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Suffolk (Harbour View)
• Williamsburg